Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2020

View Archived Issues

CRISPR sheds LICHT on brain development

Macrophages metabolically support muscle

Seeing where tau goes wrong

Hoth outlines progress within COVID-19 pipeline

Sorrento Therapeutics synthesizes multispecific antigen-binding protein complexes

New anti-CD40 antibodies described by Nankai University

Memorial Sloan-Kettering Cancer Center presents CD19 antibodies

New wee1-like protein kinase inhibitors discovered at Nuvation Bio

Roche identifies new monoglyceride lipase inhibitors

Preliminary first-in-human data for [11C]MeDAS PET tracer

BlueWillow Biologics presents preclinical data on NanoVaz and S-2P-NE01

Discovery of novel DNA-PK inhibitors as radiosensitizers

[68Ga]Desferal developed for imaging of bacterial infections

Calithera expands phase I/II trial of telaglenastat with palbociclib to include pancreatic cancer

First results for KSQ-4279 in treatment of BRCA-deficient cancers

Microbiome confounders research complicates control groups

PK and safety data for nacubactam in combination with beta-lactams

Phase IIb/III study opens in U.S. with mesdopetam for troublesome dyskinesias in Parkinson's

[18F]FSU-880 imaging evaluated in prostate cancer patients with biochemical recurrence

Hangzhou Zhengxiang Pharmaceuticals patents PI3K-gamma inhibitors

Synlogic advances SYNB-8802 into phase I study for treatment of enteric hyperoxaluria

E.U. approval of Lynparza with bevacizumab for first-line maintenance in HRD-positive ovarian cancer

Chinese clearance for phase III trial of APL-1202 for first-line nonmuscle invasive bladder cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...